# High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

> **NCT00533949** · PHASE3 · COMPLETED · sponsor: **Radiation Therapy Oncology Group** · enrollment: 544 (actual)

## Conditions studied

- Lung Cancer
- Radiation Toxicity

## Interventions

- **BIOLOGICAL:** Cetuximab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **RADIATION:** 60 Gy RT
- **RADIATION:** 74 Gy RT

## Key facts

- **NCT ID:** NCT00533949
- **Lead sponsor:** Radiation Therapy Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2013-06
- **Final completion:** 2022-05-20
- **Target enrollment:** 544 (ACTUAL)
- **Last updated:** 2022-06-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00533949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00533949, "High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00533949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*